HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Request Reprints Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (21) Citing Articles via Google Scholar Google Scholar Articles by Dowell, J. A. Articles by Foster, G. Search for Related Content PubMed PubMed Citation Articles by Dowell, J. A. Articles by Foster, G. Social Bookmarking                   What's this?

Safety and Pharmacokinetics of Coadministered Voriconazole and Anidulafungin

From Vicuron Pharmaceuticals, King of Prussia, Pennsylvania (Dr Dowell, Dr Schranz); and Pfizer Inc, New York, New York (Dr Baruch, Dr Foster).

There is considerable interest in combining echinocandin and triazole antifungal agents for treatment of invasive fungal infections; however, information is needed regarding the tolerability and potential for pharmacokinetic interactions. Anidulafungin is a semisynthetic echinocandin, and voriconazole is an extended-spectrum triazole. In a random sequence, 17 subjects received anidulafungin with placebo, voriconazole with placebo, and anidulafungin with voriconazole. Anidulafungin was administered intravenously: 200 mg on day 1, then 100 mg/d on days 2 through 4. Voriconazole was administered orally: 400 mg every 12 hours on day 1, then 200 mg every 12 hours on days 2 to 4. No dose-limiting toxicities or serious adverse events occurred, and all adverse events were mild and consistent with the known safety profiles of both drugs. Pharmacokinetic parameters were not affected by coadministration. The geometric mean ratio (90% confidence interval) of the combination/drug alone for AUC_SS was 97.4% (94.9-99.9), 97.4% (92.1-103.0), and 94.4% (87.0-102.5) for anidulafungin, voriconazole, and the voriconazole metabolite, respectively.

Key Words: Anidulafungin • voriconazole • drug interaction

Address for reprints: James A. Dowell, Vicuron Pharmaceuticals, 455 South Gulph Road, Suite 310, King of Prussia, PA 19406.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				V. Petraitis, R. Petraitiene, W. W. Hope, J. Meletiadis, D. Mickiene, J. E. Hughes, M. P. Cotton, T. Stergiopoulou, M. Kasai, A. Francesconi, et al. Combination Therapy in Treatment of Experimental Pulmonary Aspergillosis: In Vitro and In Vivo Correlations of the Concentration- and Dose- Dependent Interactions between Anidulafungin and Voriconazole by Bliss Independence Drug Interaction Analysis Antimicrob. Agents Chemother., June 1, 2009; 53(6): 2382 - 2391. [Abstract] [Full Text] [PDF]

				W. W. J. van de Sande, R. A. A. Mathot, M. T. ten Kate, W. van Vianen, M. Tavakol, B. J. A. Rijnders, and I. A. J. M. Bakker-Woudenberg Combination Therapy of Advanced Invasive Pulmonary Aspergillosis in Transiently Neutropenic Rats Using Human Pharmacokinetic Equivalent Doses of Voriconazole and Anidulafungin Antimicrob. Agents Chemother., May 1, 2009; 53(5): 2005 - 2013. [Abstract] [Full Text] [PDF]

				B. D. Damle, J. A. Dowell, R. L. Walsky, G. L. Weber, M. Stogniew, and P. B. Inskeep In Vitro and In Vivo Studies To Characterize the Clearance Mechanism and Potential Cytochrome P450 Interactions of Anidulafungin Antimicrob. Agents Chemother., March 1, 2009; 53(3): 1149 - 1156. [Abstract] [Full Text] [PDF]

				S. Jeong, P. D. Nguyen, and Z. Desta Comprehensive In Vitro Analysis of Voriconazole Inhibition of Eight Cytochrome P450 (CYP) Enzymes: Major Effect on CYPs 2B6, 2C9, 2C19, and 3A Antimicrob. Agents Chemother., February 1, 2009; 53(2): 541 - 551. [Abstract] [Full Text] [PDF]

				J. Keirns, T. Sawamoto, M. Holum, D. Buell, W. Wisemandle, and A. Alak Steady-State Pharmacokinetics of Micafungin and Voriconazole after Separate and Concomitant Dosing in Healthy Adults Antimicrob. Agents Chemother., February 1, 2007; 51(2): 787 - 790. [Abstract] [Full Text] [PDF]